Sustainable Discovery and Development of Antibiotics — Is a Nonprofit Approach the Future?
25 June 2019
Shifting to a nonprofit-driven model for development of antibiotics could encourage discovery and development of truly needed drugs that improve patient outcomes and permit more effective control over the postapproval use of antibiotics to prolong their effectiveness.
Further reading: The New England Journal of Medicine
Author(s): Travis B. Nielsen, Eric P. Brass, David N. Gilbert, John G. Bartlett, and Brad Spellberg
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
